Joel Greenblatt's DXCM Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 82,253 shares of DexCom, Inc. (DXCM) worth $5.46 M, representing 0.02% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in DXCM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2020, adding 90,800 shares. Largest reduction occurred in Q2 2020, reducing 100,308 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's DexCom (DXCM) Holding Value Over Time
Track share changes against reported price movement
Quarterly DexCom (DXCM) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +68,699 | Add 506.85% | 82,253 | $66.37 |
| Q3 2025 | -69,798 | Reduce 83.74% | 13,554 | $67.29 |
| Q2 2025 | -30,210 | Reduce 26.60% | 83,352 | $87.29 |
| Q1 2025 | -1,120 | Reduce 0.98% | 113,562 | $68.29 |
| Q4 2024 | +35,883 | Add 45.54% | 114,682 | $77.77 |
| Q3 2024 | +30,919 | Add 64.58% | 78,799 | $67.04 |
| Q2 2024 | +8,276 | Add 20.90% | 47,880 | $113.38 |
| Q1 2024 | -168 | Reduce 0.42% | 39,604 | $138.70 |
| Q4 2023 | -40,027 | Reduce 50.16% | 39,772 | $124.09 |
| Q3 2023 | +46,879 | Add 142.40% | 79,799 | $93.30 |
| Q2 2023 | -12,090 | Reduce 26.86% | 32,920 | $128.51 |
| Q1 2023 | -48,296 | Reduce 51.76% | 45,010 | $116.18 |
| Q4 2022 | +55,181 | Add 144.74% | 93,306 | $113.24 |
| Q3 2022 | +18,855 | Add 97.85% | 38,125 | $80.55 |
| Q2 2022 | -10,286 | Reduce 34.80% | 19,270 | $74.52 |
| Q1 2022 | +10,804 | Add 57.62% | 29,556 | $127.89 |
| Q4 2021 | +15,904 | Add 558.43% | 18,752 | $134.23 |
| Q3 2021 | +2,848 | New Buy | 2,848 | $136.59 |
| Q1 2021 | -6,944 | Sold Out | 0 | $0.00 |
| Q4 2020 | -3,940 | Reduce 36.20% | 6,944 | $92.45 |
| Q3 2020 | +3,944 | Add 56.83% | 10,884 | $103.09 |
| Q2 2020 | -100,308 | Reduce 93.53% | 6,940 | $101.30 |
| Q1 2020 | +90,800 | Add 552.04% | 107,248 | $67.32 |
| Q4 2019 | +16,448 | New Buy | 16,448 | $54.66 |
| Q2 2018 | -40,160 | Sold Out | 0 | $0.00 |
| Q1 2018 | +40,160 | New Buy | 40,160 | $18.55 |
| Q1 2015 | -39,660 | Sold Out | 0 | $0.00 |
| Q4 2014 | +39,660 | New Buy | 39,660 | $13.77 |
| Q3 2014 | -32,132 | Sold Out | 0 | $0.00 |
| Q2 2014 | +32,132 | New Buy | 32,132 | $9.93 |
Joel Greenblatt's DexCom Investment FAQs
Joel Greenblatt first purchased DexCom, Inc. (DXCM) in Q2 2014, acquiring 32,132 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held DexCom, Inc. (DXCM) for 30 quarters since Q2 2014.
Joel Greenblatt's largest addition to DexCom, Inc. (DXCM) was in Q1 2020, adding 107,248 shares worth $7.22 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 82,253 shares of DexCom, Inc. (DXCM), valued at approximately $5.46 M.
As of the Q4 2025 filing, DexCom, Inc. (DXCM) represents approximately 0.02% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in DexCom, Inc. (DXCM) was 114,682 shares, as reported at the end of Q4 2024.